Trivalent Influenza Virus Vaccine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Influenza
Conditions
Influenza
Trial Timeline
May 1, 2012 → Nov 1, 2012
NCT ID
NCT01579916About Trivalent Influenza Virus Vaccine
Trivalent Influenza Virus Vaccine is a approved stage product being developed by AstraZeneca for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT01579916. Target conditions include Influenza.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01579916 | Approved | Completed |
Competing Products
20 competing products in Influenza